|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.600 USD | +7.32% |
|
+66.25% | +200.00% |
| Dec. 07 | Immix Biopharma prices offering of 19.1 million shares at $5.10 per share | RE |
| Nov. 12 | Immix Biopharma, Inc. Appoints Michael Grabow as Chief Commercial Officer | CI |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Biological Products | ||||||
Total Assets | 710K | 18.19M | 14.91M | 19.93M | 22.95M | |
Interest Expense | -102K | -180K | -497 | - | - | |
Income Tax Expense | 17.55K | 6.01K | 10.27K | 26.42K | 41.04K | |
CAPEX | - | -802 | - | -52.09K | -1.18M | |
EBT | -987K | -24.38M | -8.22M | -15.57M | -21.66M | |
D&A | 2.32K | 2.47K | 2.14K | 5.47K | 115K | |
Operating Income | -311K | -1.35M | -8.22M | -16.14M | -22.67M | |
Net Income | -1M | -24.38M | -8.23M | -15.43M | -21.61M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Total Assets | 710K | 18.19M | 14.91M | 19.93M | 22.95M | |
Interest Expense | -102K | -180K | -497 | - | - | |
Income Tax Expense | 17.55K | 6.01K | 10.27K | 26.42K | 41.04K | |
D&A | 2.32K | 2.47K | 2.14K | 5.47K | 115K | |
CAPEX | - | -802 | - | -52.09K | -1.18M | |
Net Income | -1M | -24.38M | -8.23M | -15.43M | -21.61M | |
EBT | -987K | -24.38M | -8.22M | -15.57M | -21.66M | |
Operating Income | -311K | -1.35M | -8.22M | -16.14M | -22.67M |
- Stock Market
- Equities
- IMMX Stock
- Financials Immix Biopharma, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
